Chart structure looks very good to me and I think there is a chance this goes on a massive hype run this year, Our purple levels marked should not break if this is bullish.
Expecting a pre run up into the FDA event. We are having a gap arround 10. Lots of recent block buys and kind of a middle high short float.
High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR-Cas9 Editing CRISPR-Cas9 editing is a scalable technology for mapping of biological pathways, but it has been reported to cause a variety of undesired large-scale structural changes to the genome. We performed an arrayed CRISPR-Cas9 scan of the genome in primary human cells,...
The artificial intelligence (AI) trade has been blistering higher, but Wednesday featured an interesting surge. That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session.
This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. PRZ zone tested, I'll take a fade trade off it.
Biotechnology companies develop therapeutics or processes that advance medicine, pharmaceuticals, genomics, food production, and the production of biofuels. Biotech stocks are risky investments, because the development stage of the asset pipeline can take a long time and usually does not even workout in the end. A good example of a long-term successful biotech...
As the title says setup looks good - think this has bottomed and we're in the early stages of a bull trend.
RXRX: Recursion Pharmaceuticals, Inc. 2021-10-07 07:55:00 Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas
Really like the fundamentals behind this company. Did some research over the weekend and I like what this company is doing. Still trying to find itself after the recent IPO but the levels are quite simple. The daily purple lines indicating clear support and resistance. Friday closed RIGHT at IPO price so we will see what this week offers. Buying pressure is...